Albiglutide - GSK
Alternative Names: Albugon; Albumin-GLP-1 fusion protein; Albumin-glucagon-like peptide-1 fusion protein; Eperzan; GLP-1-albumin fusion protein; Glucagon-like peptide-1-albumin fusion protein; GSK 716155; Syncria®; TanzeumLatest Information Update: 05 Nov 2023
At a glance
- Originator Human Genome Sciences
- Developer GSK
- Class Albumins; Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Discontinued Heart failure; Type 1 diabetes mellitus
Most Recent Events
- 16 Jan 2018 Discontinued - Phase-II for Type-1 diabetes mellitus (Adjunctive treatment, Newly diagnosed) in France, United Kingdom, Italy, Germany and Spain (SC)
- 16 Jan 2018 Discontinued - Phase-II for Type-2 diabetes mellitus in Chile and Dominican Republic (SC)
- 16 Jan 2018 Discontinued - Phase-III for Type-2 diabetes mellitus in Albania, Japan, Mexico, Russia, Philippines, Hong Kong, Peru, Taiwan, South Korea, Australia, Brazil, Israel, South Africa, Colombia and India (SC)